-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
Figure 1: Shandong New Times Pharmaceutical's latest approved product information
Source: NMPA official website
Metformin is a first-line drug for the treatment of type 2 diabetes.
According to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
According to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
Source: new version database of Minet
Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
3 billion yuan
.
3 billion yuan
.
Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
Source: new version database of Minet
According to data from Minet.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
Source: NMPA official website, Minet database
Note: The review data statistics are as of April 15.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
Figure 1: Shandong New Times Pharmaceutical's latest approved product information
Source: NMPA official website
Metformin is a first-line drug for the treatment of type 2 diabetes.
According to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
According to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
Source: new version database of Minet
Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
3 billion yuan
.
3 billion yuan
.
Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
Source: new version database of Minet
According to data from Minet.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
Source: NMPA official website, Minet database
Note: The review data statistics are as of April 15.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 15, NMPA released the latest drug approval information, and Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
.
In recent years, Shandong New Era Pharmaceuticals has increased its efforts in the field of diabetes medication.
The company's first insulin product, recombinant insulin glargine injection, has been submitted for production and is under review
.
Figure 1: Shandong New Times Pharmaceutical's latest approved product information
Source: NMPA official website
Metformin is a first-line drug for the treatment of type 2 diabetes.
According to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
hospital hospital hospitalAccording to the data from Minet.
com, in 2020, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, metformin has become a non-insulin type.
The TOP1 variety of hypoglycemic drugs, with sales of more than 6.
2 billion yuan
.
Figure 2: Approved diabetes drugs by Shandong New Era Pharmaceuticals
Source: new version database of Minet
Shandong New Times Pharmaceutical has won miglitol tablets, glimepiride dropping pills and lipoic acid injection in the field of diabetes medication, among which glimepiride dropping pills are the first imitations in China, while miglitol tablets, In 2020, the sales volume of lipoic acid injection in public medical institutions in China will reach 500 million yuan and 1.
3 billion yuan
.
3 billion yuan
.
Figure 3: Diabetes drugs reported by Shandong New Era Pharmaceuticals and under review
Source: new version database of Minet
According to data from Minet.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
com, the company's application for the market of recombinant insulin glargine injection submitted in 2020 is under review and approval.
This product is expected to become the company's next approved diabetes drug, and it will also be the company's first approved insulin.
product, worth looking forward to
.
Source: NMPA official website, Minet database
Note: The review data statistics are as of April 15.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
